Drug Interactions between magnesium glycinate and Niva Thyroid

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Concurrent administration of simethicone, sucralfate and/or antacid preparations may decrease the oral bioavailability of levothyroxine. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to polyvalent cations, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract. Additionally, agents that affect intragastric pH may reduce levothyroxine absorption. There have been case reports suggesting decreased efficacy of levothyroxine during coadministration of aluminum- and magnesium-containing antacids, as well as other products containing polyvalent cations such as calcium and iron. In one report, a man stabilized on levothyroxine 150 mcg/day developed significantly increased serum thyrotropin (thyroid-stimulating hormone, or TSH) levels while taking an aluminum and magnesium hydroxide antacid. The apparent interaction was also observed on two subsequent rechallenges. Other case reports have described increased dosage requirements of levothyroxine during antacid use. It is not known whether this interaction occurs with other thyroid hormone preparations.

MANAGEMENT: It is recommended to separate the times of administration of thyroid replacement hormones and simethicone, sucralfate, antacids or other antacid-containing preparations (e.g., didanosine buffered tablets or pediatric oral solution) by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.